Loading
Radiochemist who built the zirconium-89 immuno-PET platform and MSKCC's radiopharmaceutical pipeline.
Jason Lewis developed methods for labelling antibodies with zirconium-89 that made immuno-PET a clinical reality, including 89Zr-trastuzumab and 89Zr-J591 PSMA imaging, and leads a laboratory translating new radiotracers and radioligand therapies from chemistry to first-in-human trials. He directs radiochemistry at MSKCC and has trained many of the field's leaders.
| Title | Journal | Year |
|---|---|---|
| 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo | Journal of Nuclear Medicine | 2010 |
| Immuno-PET of HER2-positive breast cancer with 89Zr-trastuzumab: a first-in-human study | Journal of Nuclear Medicine | 2016 |
Shares Journal of Nuclear Medicine, PSMA, Radioligand therapy (beta emitters).
Shares Journal of Nuclear Medicine, PSMA.
Shares PSMA, Radioligand therapy (beta emitters), Memorial Sloan Kettering Cancer Center.
Shares Journal of Nuclear Medicine, PSMA, Radioligand therapy (beta emitters).
Shares Radioligand therapy (beta emitters), HER2.
Shares PSMA, Radioligand therapy (beta emitters).
Shares Radioligand therapy (beta emitters) and the tag theranostics.